A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome

British Journal of Haematology

Volumn 103, Issue 1, 1998, Pages 176-188

  Gersuk, Geoffrey M ^a   Beckham, Cassandra ^a   Loken, Michael R ^d   Kiener, Peter ^b   Anderson, Jeanne E ^a   Farrand, Alan ^a   Troutt, Anthony B ^c   Ledbetter, Jeffrey A ^b   Deeg, H Joachim ^a,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c AMGEN INC   (United States)

^d HEMATOLOGICS INC   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Fas Fas L; Haemopoiesis; MDS; TNF

Indexed keywords

FAS ANTIGEN; FAS LIGAND; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; BONE MARROW CELLS; BONE MARROW DISEASES; CHILD; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HUMANS; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; MULTIPLE MYELOMA; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031656518     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00933.x     Document Type: Article

References (60)

1. Alderson, M.R., Tough, T.W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K.A., Goodwin, R.G., Smith, C.A., Ramsdell, F. & Lynch, D.H. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. Journal of Experimental Medicine, 181, 71-77.
2. Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W. & Yuan, J. (1996) Human ICE/ CED-3 protease nomenclature. (Letter). Cell, 87, 171.
3. Badley, A.D., McElhinny, J.A., Leibson, P.J., Lynch, D.H., Alderson, M.R. & Paya, C.V. (1996) Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Journal of Virology, 70, 199-206.
4. Berenson, R.J., Bensinger, W.I. & Kalamasz, D. (1986) Positive selection of viable cell populations using avidin-biotin immunoadsorption. Journal of Immunological Methods, 91, 11-19.
5. Bogdanovic, A.D., Jankovic, G.M., Colovic, M.D., Trpinac, D.P. & Bumbasirevic, V.Z. (1996) Apoptosis in bone marrow of myelodysplastic syndrome patients. (Letter). Blood, 87, 3064.
6. Cascino, I., Papoff, G., De Maria, R., Testi, R. & Ruberti, G. (1996) Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. Journal of Immunology, 156, 13-17.
7. Dexter, T.M., Allen, T.D. & Lajtha, L.G. (1977) Conditions controlling the proliferation of haemopoietic stem cells in vitro. Journal of Cellular Physiology, 91, 335-344.
8. Dhein, J., Walczak, H., Baumler, C., Debatin, K.M. & Krammer, P.H. (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373, 438-441.
9. Ganser, A., Seipelt, G. & Hoelzer, D. (1991) The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes. American Journal of Clinical Oncology, 14, (Suppl. 1), S34-S39.
10. Gersuk, G.M., Lee, J.W., Beckham, C.A., Anderson, J. & Deeg, H.J. (1996) Fas (CD95) receptor and fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome (tetter). Blood, 88, 1122-1123.
11. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
12. Greenberg, P.L. (1992) Treatment of myelodysplastic syndromes with hemopoietic growth factors. Seminars in Oncology, 19, 106-114.
13. Greinix, H.T., Storb, R. & Bartelmez, S.H. (1992) Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules. Blood, 80, 1950-1956.
14. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. & Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363-1366.
15. Hatake, K., Tomizuka, H., Ikeda, M., Tsunoda, J., Hoshino, Y., Ohtsuki, T., Kasahara, T. Yonehara, S. & Miura, Y. (1994) The presence of apoptosis in refractory anemia of myelodysplasia. Molecular Biology of Haematopoieais (ed. by N. Abraham, R. K. Shadduck, A. S. Levine and F. Takaku), p. 127. Intercept Ltd. Andover.
16. Heyman, M.R. (1991) Recent advances in biology and treatment of myelodysplasia. Current Opinion in Oncology, 3, 44-53.
17. Hong, D.-S., Beckham, C., Huss, R., Lee, J.W., Hockenbery, D., Ledbetter, J.A. & Deeg, H.J. (1995) Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand. Blood, 86, 3341-3352.
18. Iijima, N., Miyamura, K., Itou, T., Tanimoto, M., Sobue, R. & Saito, H. (1997) Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood, 90, 4901-4909.
19. Kiener, P.A., Davis, P.M., Starling, G.C., Mehlin, C., Klebanoff, S.J., Ledbetter, J.A. & Liles, W.C. (1997) Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. Journal of Experimental Medicine, 185, 1511-1516.
20. Krammer, P.H., Dhein, J., Walczak, H., Behrmann, I., Mariani, S., Matiba, B., Fath, M., Daniel, P.T., Knipping, E., Westendorp, M.O., Stricker, K., Baumler, C., Hellbardt, S., Germer, M., Peter, M.E. & Debatin, K.M. (1994) The role of APO-1-mediated apoptosis in the immune system. Immunological Reviews, 142, 175-191.
21. Lee, J.W., Gersuk, G.M., Kiener, P.A., Beckham, C., Ledbetter, J.A. & Deeg, H.J. (1997) HLA-DR-triggered inhibition of hematopoiesis involves Fas/Fas-ligand interactions and is prevented by c-kit ligand. Journal of Immunology, 159, 3211-3219.
22. Liles, W.C., Kiener, P.A., Ledbetter, J.A., Aruffo, A. & Klebanoff, S.J. (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. Journal of Experimental Medicine, 184, 429-440.
23. Loken, M.R., Terstappen, L.W.M.M., Civin, C.I. & Fackler, M.J. (1992) Flow cytometric characterization of erythroid, lymphoid and monomyeloid lineages in normal human bone marrow. Flow Cytometry in Hermatology (ed. by O. D. Laerum and R. Bjerksnes), p. 31. Academic Press, New York.
24. + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 3183-3190.
25. + cells of patients with aplastic anaemia. British Journal of Haematology, 91, 245-252.
26. Maekawa, K., Imagawa, N., Nagamatsu, M. & Harada, S. (1994) Molecular cloning of a novel protein-tyrosine phosphatase containing a membrane-binding domain and GLGF repeats. FEBS Letters, 337, 200-206.
27. Mayer, R.J. & Canellos, G.P. (1996) Primary myelodysplastic syndrome and secondary preleukemic disorders. Leukemia (ed. by E. S. Henderson, T. A. Lister and M. F. Greaves), p. 513. Saunders, Philadelphia.
28. Mohler, K.M., Torrance, D.S., Smith, C.A., Goodwin, R.G., Stremler, K.E., Fung, V.P., Madani, H. & Widmer, M.B. (1997) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. Journal of Immunology, 151, 1548-1561.
29. Moller, N.P., Moller, K.B., Lammers, R., Kharitonenkov, A., Sures, I. & Ullrich, A. (1994) Src kinase associates with a member of a distinct subfamily of protein-lyrosine phosphatases containing an ezrin-like domain. Proceedings of the National Academy of Sciences of the United States of America, 91, 7477-7481.
30. Mufti, G.J. (1992) A guide to risk assessment in the primary myelodysplastic syndrome. Hematology/Oncology Clinics of North America, 6, 587-606.
31. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E. & Dixit, V.M. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85, 817-827.
32. Nagata, S. (1997) Apoptosis by death factor. Cell, 88, 355-365.
33. Nagata, S. & Golstein, P. (1995) The Fas death factor. Science, 267, 1449-1456.
34. Nagler, A., MacKichan, M.L., Negrin, R.S., Donlon, T. & Greenberg, P.L. (1995) Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. Leukemia, 9, 30-59.
35. Noel, P. & Solberg, L.A., Jr (1992) Myelodysplastic syndromes: pathogenesis, diagnosis and treatment. Critical Reviews in Oncology/Hematology, 12, 193-215.
36. O'Connell, J., O'Sullivan, G.C., Collins, J. & Shanahan, F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medicine, 184, 1075-1082.
37. Rajapaksa, R., Ginzton, N., Rott, L.S. & Greenberg, P.L. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275-4287.
38. + T cells. Nature, 376, 181-184.
39. Raza, A., Gezer, S., Gregory, S.A., Venugopal, P., Kaizer, U., Dong, L.M., Span, L., Hines, C., Thomas, R., Alvi, S., Mundle, S.D., Shetty, V., Borok, R., Loew, J., Reza, S., Robin, E.L. Rifkin, S.D., Alston, D., Hernandez, B.M., Shah, R., Hsu, W.-T., Dar, S. & Preisler, H.D. (1996a) Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). (Abstract). Blood, 88, 580a.
40. Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V. Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S. & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
41. Raza, A., Mundle, S., Shetty, V. Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H., Gregory, S. & Preisler, H. (1996b) A paradigm shift in myelodysplastic syndromes. Leukemia, 10, 1648-1652.
42. lo human marrow cells after in vitro cytokine exposure. Blood, 85, 1480-1487.
43. Sato, T., Irie, S., Kitada, S. & Reed, J.C. (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science, 268, 411-415.
44. Selleri, C., Sato, T., Del Vecchio, L., Luciano, L., Barrett, A.J., Rotoli, B., Young, N.S. & Maciejewski, J.P. (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood, 89, 957-964.
45. Shetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J., Gregory, S., Rifkin, S., Gezer, S., Parcharidou, A., Venugopal, P., Shah, R., Hernandez, B., Klein, M., Alston, D., Robin, E., Dominquez, C. & Raza, A. (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Research, 20, 891-900.
46. Sievers, E.L., Lange, B.J., Buckley, J.D., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., Shults, K.E., Bernstein, I.D. & Loken, M.R. (1996) Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute, 88, 1483-1488.
47. Smith, C.A., Farrah, T. & Goodwin, R.G. (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76, 959-962.
48. Smith, M.A. & Smith, J.G. (1991) The occurrence subtype and significance of huemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leukemia Research, 15, 597-601.
49. Srour, E.F., Brandt, J.E., Briddell, R.A., Grigsby, S., Leemhuis, T. & Hoffman, R. (1993) Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood, 81, 661-669.
50. Stelzer, G.T., Shults, K.E. & Loken, M.R. (1995) CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Annals of the New York Academy of Sciences, 677, 265-280.
51. Suda, T. & Nagata, S. (1994) Purification and characterization of the Fas-ligand that induces apoptosis. Journal of Experimental Medicine, 179, 873-879.
52. Suda, T., Okazaki, T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K. & Nagata, S. (1995) Expression of the Fas ligand in cells of T cell lineage. Journal of Immunology, 154, 3806-3813.
53. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169-1178.
54. Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C. & Eaves, C.J. (1990) Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proceedings of the National Academy of Sciences of the United States of America, 87, 3584-3588.
55. Tanaka, M., Suda, T. Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A.H. & Nagata, S. (1996) Fas ligand in human serum. Nature Medicine, 2, 317-322.
56. Terstappen, L.W., Safford, M., Konemann, S., Loken, M.R., Zurlutter, K., Buchner, T., Hiddemann, W. & Wormann, B. (1992) Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia, 6, 70-80.
57. Vignaux, F., Vivier, E., Malissen, B., Depraetere, V., Nagata, S. & Golstein, P. (1995) TCR/CD3 coupling to Fas-based cytotoxicity. Journal of Experimental Medicine, 181, 781-786.
58. Watanabe-Fukunaga, R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A. & Nagata, S. (1992) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. Journal of Immunology, 148, 1274-1279.
59. Yamaguchi, M., Gersuk, G., Nadler, S. & Deeg, H.J. (1996) HLA-DR mediated apoptosis and inhibition of hematopoiesis involves upregulation of tumor necrosis factor alpha. (Abstract). Experimental Hematology, 24, 1100.
60. Yoshida, Y. (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia, 7, 144-146.